Curated News
By: NewsRamp Editorial Staff
November 13, 2025

Lantern Pharma Reports 48% Clinical Benefit in AI-Driven Cancer Trial

Discuss on LinkedIn Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's LP-184 shows 48% clinical benefit rate, positioning it for competitive advantage in oncology markets with $15 billion annual potential.
  • Lantern Pharma's AI platform analyzed 200 billion data points to advance LP-184 through Phase 1a trials and establish a 0.39 mg/kg Phase 2 dose.
  • Lantern Pharma's AI-driven oncology programs aim to provide life-changing therapies for hundreds of thousands of cancer patients worldwide.
  • Lantern Pharma uses AI with 200+ machine learning algorithms to discover cancer drugs, achieving 48% clinical benefit in recent trials.

Impact - Why it Matters

This development represents a significant advancement in AI-driven oncology drug development, potentially accelerating the delivery of effective cancer treatments to patients. For cancer patients facing limited treatment options, particularly those with difficult-to-treat cancers like TNBC and NSCLC with specific mutations, these AI-optimized therapies could offer new hope. The 48% clinical benefit rate in Phase 1a trials suggests these treatments may be more effective than traditional approaches, while the AI-driven development process could substantially reduce the time and cost typically required to bring new cancer drugs to market. This matters because it demonstrates how artificial intelligence is transforming cancer treatment discovery, potentially making personalized, effective therapies available faster and to more patients who desperately need them.

Summary

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, reported significant progress in its third-quarter 2025 results, highlighting major advancements across its clinical pipeline. The company announced completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which demonstrated a remarkable 48% clinical benefit rate at or above the therapeutic dose threshold. This promising candidate showed a favorable safety profile and strong biomarker correlations, with pharmacokinetic data establishing a recommended Phase 2 dose of 0.39 mg/kg. Lantern Pharma also outlined plans for upcoming Phase 1b/2 studies targeting triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) with STK11/KEAP1 co-mutations, and bladder cancer, positioning the company for multiple near-term catalysts.

The company's proprietary AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and more than 200 advanced ML algorithms to accelerate drug discovery and development. This powerful technology platform has enabled Lantern Pharma to build a robust pipeline of therapies spanning multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate (ADC) program. The company reported additional positive developments, including regulatory clarity for its pediatric CNS cancer program following a productive FDA Type C meeting and increased commercial interest for LP-284. With an estimated combined annual market potential exceeding $15 billion USD, Lantern Pharma's AI-driven approach represents a transformative force in oncology drug development that could provide life-changing therapies to hundreds of thousands of cancer patients worldwide.

Investors and stakeholders can access the full press release through the InvestorWire platform, which serves as part of the Dynamic Brand Portfolio within the Investor Brand Network (IBN). This specialized communications platform provides advanced wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release optimization, and comprehensive social media distribution through IBN's extensive network. The latest news and updates relating to Lantern Pharma are available in the company's dedicated newsroom, providing ongoing access to developments across the company's growing portfolio of innovative oncology treatments and AI-driven drug discovery initiatives.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Reports 48% Clinical Benefit in AI-Driven Cancer Trial

blockchain registration record for this content.